These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2083186)

  • 81. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
    Conte PF; Bruzzone M; Carnino F; Gadducci A; Algeri R; Bellini A; Boccardo F; Brunetti I; Catsafados E; Chiara S; Foglia G; Gallo L; Iskra L; Mammoliti S; Parodi G; Ragni N; Rosso R; Rugiati S; Rubagotti A
    J Clin Oncol; 1996 Feb; 14(2):351-6. PubMed ID: 8636743
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Results of intraperitoneal chemotherapy of ovarian cancer].
    de Gramont A; Marpeau L; Demuynck B; Louvet C; Varette C; Gonzalez-Canali G; Pigné A; Herbulot P; Lagadec B; Cady J
    J Gynecol Obstet Biol Reprod (Paris); 1991; 20(3):387-92. PubMed ID: 1869784
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 85. High-dose carboplatin in refractory ovarian cancer patients.
    Ozols RF; Ostchega Y; Curt G; Young RC
    J Clin Oncol; 1987 Feb; 5(2):197-201. PubMed ID: 3543243
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.
    Kaye SB; Lewis CR; Paul J; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM
    Lancet; 1992 Aug; 340(8815):329-33. PubMed ID: 1353804
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study.
    Zamagni C; Martoni A; Cacciari N; Gentile A; Pannuti F
    Am J Clin Oncol; 1998 Oct; 21(5):491-7. PubMed ID: 9781607
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
    Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
    van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
    Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study.
    Lambert HE; Rustin GJ; Gregory WM; Nelstrop AE
    Ann Oncol; 1997 Apr; 8(4):327-33. PubMed ID: 9209661
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
    Bolis G; Colombo N; Pecorelli S; Torri V; Marsoni S; Bonazzi C; Chiari S; Favalli G; Mangili G; Presti M
    Ann Oncol; 1995 Nov; 6(9):887-93. PubMed ID: 8624291
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.
    Jakobsen A; Bertelsen K; Andersen JE; Havsteen H; Jakobsen P; Moeller KA; Nielsen K; Sandberg E; Stroeyer I
    J Clin Oncol; 1997 Jan; 15(1):193-8. PubMed ID: 8996142
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens.
    Repetto L; Chiara S; Pace M; Guido T; Bruzzone M; Oliva C; Murolo C; Conte PF; Rosso R
    Tumori; 1990 Jun; 76(3):274-7. PubMed ID: 2195729
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
    Smyth JF; Bowman A; Perren T; Wilkinson P; Prescott RJ; Quinn KJ; Tedeschi M
    Ann Oncol; 1997 Jun; 8(6):569-73. PubMed ID: 9261526
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Ovarian cancer, from the laboratory to the clinic: challenges for the future.
    Kaye SB
    Ann Oncol; 1996 Jan; 7(1):9-13. PubMed ID: 9081399
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Percutaneous catheterization of the peritoneal cavity guided by ultrasonography in the treatment of intraabdominal carcinoma of the ovary.
    Bennedbaek O; Bartholdy NJ; Fisker P; Panduro J
    Eur J Gynaecol Oncol; 1989; 10(5):300-1. PubMed ID: 2680508
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Staff NP; Cavaletti G; Islam B; Lustberg M; Psimaras D; Tamburin S
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2(Suppl 2):S26-S39. PubMed ID: 31647151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.